PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma
Alok R. Singh(UC San Diego Health System), Donald L. Durden(Levine Cancer Institute)
Cited by 31
Related Papers
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
|Cancer Chemotherapy and Pharmacology|2010|38